Jeff Mack Appointed New CFO at Potrero Medical

Jeff Mack is joining the Potrero Medical executive leadership team as its Chief Financial Officer (CFO) and will report to CEO Joe Urban.

Jeff Mack brings more than 30 years of finance and capital markets experience to Potrero Medical. He also has in-depth knowledge of scaling medical technology startups into significant success stories.

“I couldn’t be more thrilled to welcome a well-respected healthcare leader like Jeff. He will undoubtedly make an immediate impact as we prepare for a monumental year in our company’s history,” said Joe Urban, CEO of Potrero Medical. “I am particularly impressed with Jeff’s track record of success at multiple MedTech companies. I know that he will be coming to Potrero with the experience, momentum, and powerful strategies to help Potrero achieve great success.”

Jeff Mack comes to Potrero with a long history of helping companies raise both private and public financing. Most recently, he led finance at Outset Medical, an innovative hemodialysis company. While at Outset, Jeff played a key role in raising over $250M through the company’s private financing transactions. Along with leading the company financially he also oversaw the human resources and information technology groups where improved systems and processes were deployed to support Outset’s rapid growth.

“I am particularly impressed with Potrero’s vision around protecting the kidney, and the passion and strong alignment the Potrero team demonstrates every day,” shared Mack. “Coming from the hemodialysis industry, I appreciate the tremendous importance of kidney health.”

Potrero Medical has globally launched its Accuryn® Monitoring System to enable precision fluid management while developing predictive algorithms for critical events such as Acute Kidney Injury and Intra-Abdominal Hypertension.

“I’m committed to helping Potrero build on its recent momentum and allocate resources to achieve its greatest priorities. It will be an exciting year for the team.”

Jeff has already started his role last month, most recently attending meetings with Potrero leadership during the 2020 JP Morgan Healthcare Conference.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”